BMS Trials: Hematology

Although we wish we could see you in person, we are happy to provide you with this interactive clinical trial finder during this time of virtual connection.

Explore our recruiting trials by disease area and phase, and click on a trial to see its full details.

Filter by Disease Area and Trial Phase
  • Currently recruiting
  • Recruiting soon
Acute Myeloid Leukemia

CC-90009

Cereblon/E3 ligase modulator

Phase 1

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Advanced Hematologic Disorders

BMS-986158

BET (BRD4) small-molecule inhibitor

Phase 2
Phase 1

Study of BMS-986158 in Subjects With Select Advanced Cancers (BET)

Lymphoma/CLL

Romidepsin

Histone deacetylase inhibitor

ISTODAX® for Intravenous Infusion Drug Use Results Survey – Relapsed or Refractory Peripheral T-Cell Lymphoma

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 3

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 2

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 2

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 1
Phase 2

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 2

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 1
Phase 2

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 1

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 1
Phase 2

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

Lymphoma/CLL

Liso-cel

Anti–CD 19 CAR T cells

Phase 2

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD)

Lymphoma/CLL

Liso-cel, ide-cel

Gene-modified T cells

Phase 2
Phase 3

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Lymphoma/CLL

Nivolumab + anti-CD30 (ADC)

Anti–PD-1 + anti-CD30 (ADC)

Phase 2

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin’s Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (CheckMate 744)

Lymphoma/CLL

Azacitidine (CC-486)

Oral HMA

Phase 3

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator’s Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Lymphoma/CLL

CC-90010

BET inhibitor

Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin’s Lymphomas

Lymphoma/CLL

CC-95775

BET inhibitor

Phase 1

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma/CLL

CC-99282

Cereblon/E3 ligase modulator

Phase 1

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)

Lymphoma/CLL

CC-99282

Cereblon/E3 ligase modulator

Phase 1

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma/CLL

CC-95251

Anti-SIRPα antibody

Phase 1

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

Lymphoma/CLL

CC-90011

LSD1 inhibitor

Phase 1

A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin’s Lymphomas

Lymphoma/CLL

AG-270

MAT2A inhibitor

Phase 1

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Lymphoma/CLL

Iberdomide

Cereblon/E3 ligase modulator

Phase 1

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Lymphoma/CLL

CC-97540

CD19 NEX T

Phase 1

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma/CLL

TRPH-222

CD22 ADC (TriPhase)

Phase 1

Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

Multiple Myeloma

ide-cel

Anti-BCMA CAR T cells

Phase 3

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Multiple Myeloma

ide-cel

Anti-BCMA CAR T cells

Phase 2

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

Multiple Myeloma

ide-cel

Anti-BCMA CAR T cells

Phase 1

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

Multiple Myeloma

Iberdomide

Cereblon/E3 ligase modulator

Phase 1
Phase 2

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Multiple Myeloma

Iberdomide

Cereblon/E3 ligase modulator

Phase 2

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)

Multiple Myeloma

CC-99712

Anti-BCMA antibody-drug conjugate

Phase 1

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

orva-cel

Anti-BCMA CAR T cells

Phase 1
Phase 2

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)

Multiple Myeloma

CC-93269

Anti-BCMA T-cell engager

Phase 1

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

CC-92480

Cereblon/E3 ligase modulator

Phase 1

A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

CC-92480

Cereblon/E3 ligase modulator

Phase 1
Phase 2

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

CC-98633

BCMA NEX T CAR T cells

Phase 1

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Liso-cel, ide-cel

Gene-modified T cells

Phase 2
Phase 3

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Myelodysplastic Syndromes

Luspatercept-aamt

Erythroid maturation agent

Phase 2

Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions (COMMANDS)

Myelodysplastic Syndromes

Luspatercept-aamt

Erythroid maturation agent

Phase 3

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Myelodysplastic Syndromes

Luspatercept-aamt

Erythroid maturation agent

Phase 3

A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Myelodysplastic Syndromes

CC-90009

Cereblon/E3 ligase modulator

Phase 1

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Myelofibrosis

Fedratinib

JAK2 inhibitor

Phase 3

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Myelofibrosis

Fedratinib

JAK2 inhibitor

Phase 3

A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia (FREEDOM)

Myelofibrosis

Luspatercept-aamt

Erythroid maturation agent

Phase 2

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Myelofibrosis

Luspatercept-aamt

Erythroid maturation agent

Phase 3

A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Myelofibrosis

Luspatercept-aamt

Erythroid maturation agent

Phase 3

A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

No results found. Try adjusting filters to view more results